IV 50-100 mg/m2 for 5 consecutive days w/ a repetition after 2-3 wk; or 120-150 mg/m2 on day 1, 3 & 5 of the therapy, w/ a repetition of the therapy cycle after 2-3 wk. Oral 50 mg/m2 on days 1-21 w/ repetition on day 28; 4-6 repetitions should be carried out.
Contraindications
Hypersensitivity to podophylline & its derivatives. Severe hepatic & renal dysfunction; pregnancy & lactation; severe myelosuppression. Childn <2 yr.
Special Precautions
Previous myelosuppression therapy, varicella, herpes zoster, mucous membrane infections, MI. Alcohol abuse. Regular monitoring of haematologic parameters & blood levels. Mucous membrane infection; bone fractures. Orally vaccinated w/ poliovirus. May impair ability to drive or operate machinery.
Adverse Reactions
Inhibition of haematopoietic system, alopecia, GI upsets; hypotension, allergic reactions, neuropathy, anemia.
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Manage Account
Change Password
Sign Out
